Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases

Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavgacı, Akif, Kula, Serdar, İncedere, Fatma, Terlemez, Semiha, Tunaoğlu, Fatma Sedef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bayçınar Medical Publishing 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012979/
https://www.ncbi.nlm.nih.gov/pubmed/36926146
http://dx.doi.org/10.5606/tgkdc.dergisi.2023.23748
_version_ 1784906719734792192
author Kavgacı, Akif
Kula, Serdar
İncedere, Fatma
Terlemez, Semiha
Tunaoğlu, Fatma Sedef
author_facet Kavgacı, Akif
Kula, Serdar
İncedere, Fatma
Terlemez, Semiha
Tunaoğlu, Fatma Sedef
author_sort Kavgacı, Akif
collection PubMed
description Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-related symptoms, or in cases where epoprostenol treatment should be reduced due to side effects. In this article, we describe three pediatric cases of pulmonary arterial hypertension in whom subcutaneous treprostinil was used.
format Online
Article
Text
id pubmed-10012979
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Bayçınar Medical Publishing
record_format MEDLINE/PubMed
spelling pubmed-100129792023-03-15 Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases Kavgacı, Akif Kula, Serdar İncedere, Fatma Terlemez, Semiha Tunaoğlu, Fatma Sedef Turk Gogus Kalp Damar Cerrahisi Derg Brief Report Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-related symptoms, or in cases where epoprostenol treatment should be reduced due to side effects. In this article, we describe three pediatric cases of pulmonary arterial hypertension in whom subcutaneous treprostinil was used. Bayçınar Medical Publishing 2023-01-30 /pmc/articles/PMC10012979/ /pubmed/36926146 http://dx.doi.org/10.5606/tgkdc.dergisi.2023.23748 Text en Copyright © 2023, Turkish Society of Cardiovascular Surgery https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Brief Report
Kavgacı, Akif
Kula, Serdar
İncedere, Fatma
Terlemez, Semiha
Tunaoğlu, Fatma Sedef
Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases
title Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases
title_full Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases
title_fullStr Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases
title_full_unstemmed Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases
title_short Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases
title_sort subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: a report of three cases
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012979/
https://www.ncbi.nlm.nih.gov/pubmed/36926146
http://dx.doi.org/10.5606/tgkdc.dergisi.2023.23748
work_keys_str_mv AT kavgacıakif subcutaneoususeoftreprostinilinpediatricpulmonaryhypertensionpatientsareportofthreecases
AT kulaserdar subcutaneoususeoftreprostinilinpediatricpulmonaryhypertensionpatientsareportofthreecases
AT incederefatma subcutaneoususeoftreprostinilinpediatricpulmonaryhypertensionpatientsareportofthreecases
AT terlemezsemiha subcutaneoususeoftreprostinilinpediatricpulmonaryhypertensionpatientsareportofthreecases
AT tunaoglufatmasedef subcutaneoususeoftreprostinilinpediatricpulmonaryhypertensionpatientsareportofthreecases

Ejemplares similares